Expression of the cancer testis antigen IGF2BP3 in colorectal cancers; IGF2BP3 holds promise as a specific immunotherapy target | Zendy

HMC Shantha Kumara | Zendy; Daniel D. Kirchoff | Zendy; Otávia L. Caballero | Zendy; Tao Su | Zendy; Aqeel Ahmed | Zendy; Sonali A. Herath | Zendy; Linda Njoh | Zendy; Vesna Cekic | Zendy; Andrew Simpson | Zendy; Carlos CordonCardo | Zendy; Richard L. Whelan | Zendy

Open Access

Expression of the cancer testis antigen IGF2BP3 in colorectal cancers; IGF2BP3 holds promise as a specific immunotherapy target

Author(s) -

HMC Shantha Kumara,

Daniel D. Kirchoff,

Otávia L. Caballero,

Tao Su,

Aqeel Ahmed,

Sonali A. Herath,

Linda Njoh,

Vesna Cekic,

Andrew Simpson,

Carlos CordonCardo,

Richard L. Whelan

Publication year - 2015

Publication title -

oncoscience

Language(s) - English

Resource type - Journals

ISSN - 2331-4737

DOI - 10.18632/oncoscience.174

Subject(s) - immunohistochemistry , pathology , biomarker , cancer , colorectal cancer , messenger rna , lymph node , tissue microarray , cancer research , medicine , biology , gene , biochemistry

IGF2BP3 (IMP3) is a mRNA binding protein that regulates IGF2 translation and function during embryogenesis. Because IGF2BP3 is undetectable in adult human tissues except the testis, and increased IGF2BP3 expression has been noted in several cancers, it is considered a cancer testis (CT) protein. IGF2BP3 mRNA expression in colorectal cancers (CRC) has not been well studied. This study's aim was to quantitatively assess IGF2BP3 mRNA expression in CRC and, thus, determine if IGF2BP3 has potential as a vaccine target.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research